RALEIGH, NC / ACCESSWIRE / September 1, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage firm pioneering novel therapies for folks with uncommon or debilitating digestive ailments, right this moment introduced that the corporate will take part on the Forty fourth European Society for Medical Diet and Metabolism (ESPEN) Congress happening September 3-6, 2022, in Vienna.
9 Meters could have an in-person exhibit positioned at sales space #9 within the exhibition corridor on the Messe Wien Exhibition & Congress Heart. Representatives of the Firm shall be current on web site to deal with medical questions on the Firm’s product pipeline, notably vurolenatide for brief bowel syndrome (SBS). 9 Meters just lately reported constructive preliminary Part 2 outcomes for vurolenatide in SBS, a uncommon illness wherein sufferers are incapable of sustaining correct diet and hydration by means of regular oral consumption alone on account of a bodily or practical lack of a portion of the intestines. Along with exhibiting, 9 Meters will even be sponsoring the ESPEN occasion.
“We stay up for attending ESPEN in particular person this yr and connecting with healthcare professionals specializing in scientific diet and its function in sure GI problems together with SBS,” stated John Temperato, President & Chief Govt Officer of 9 Meters Biopharma. “We’re excited to be accessible to share details about our product pipeline with these attending the Congress.”
About 9 Meters Biopharma
9 Meters Biopharma, Inc. is a clinical-stage firm pioneering novel therapies for folks with uncommon digestive ailments, GI circumstances with unmet wants, and debilitating problems wherein the biology of the intestine is a contributing issue. 9 Meters is growing vurolenatide, a proprietary Part 2 long-acting GLP-1 agonist, for SBS; larazotide, a decent junction regulator for MIS-C; and several other close to clinical-stage belongings.
For extra data please go to www.9meters.com or observe 9 Meters on Twitter, LinkedIn and Fb.
Ahead-Trying Statements
This press launch consists of forward-looking statements primarily based upon 9 Meters’ present expectations. Ahead-looking statements embody, however should not restricted to, statements that categorical our intentions, beliefs, expectations, methods, predictions, anticipated milestones, and some other statements regarding our future actions or different future occasions or circumstances. These statements are primarily based on present expectations, estimates and projections about our enterprise primarily based, partly, on assumptions made by administration. Precise outcomes and the timing of occasions may differ materially from these anticipated in such forward-looking statements on account of varied dangers and uncertainties, which embody, with out limitation: dangers associated to our skill to efficiently implement our strategic plans, together with reliance on our lead product candidate; uncertainties related to the scientific improvement and regulatory approval of product candidates, together with reliance on blinded knowledge; uncertainties in acquiring profitable scientific outcomes for product candidates and sudden prices that will consequence therefrom; dangers associated to the shortcoming of 9 Meters to acquire enough further capital to proceed to advance these product candidates and its preclinical packages, together with in gentle of present inventory market circumstances; dangers associated to the failure to comprehend any worth from product candidates and preclinical packages being developed and anticipated to be developed in gentle of inherent dangers and difficulties concerned in efficiently bringing product candidates to market; mental property dangers; the impression of COVID-19 on our operations, enrollment in and timing of scientific trials; dangers associated to leveraging the Firm by borrowing cash underneath the debt facility and compliance with its phrases; threat of delisting from Nasdaq; reliance on collaborators; reliance on analysis and improvement companions; dangers associated to cybersecurity and knowledge privateness; and dangers related to buying and growing further compounds. These and different dangers and uncertainties are extra absolutely described in periodic filings with the SEC, together with the components described within the part entitled “Danger Components” in 9 Meters’ Annual Report on Type 10-Okay for the yr ended December 31, 2021, as amended or supplemented by our Quarterly Stories on Type 10-Q and in different filings that 9 Meters has made and future filings 9 Meters will make with the SEC. You shouldn’t place undue reliance on these forward-looking statements, that are made solely as of the date hereof or as of the dates indicated within the forward-looking statements. 9 Meters expressly disclaims any obligation or enterprise to launch publicly any updates or revisions to any forward-looking statements contained herein to mirror any change in its expectations with regard thereto or any change in occasions, circumstances, or circumstances on which any such statements are primarily based.
Company Contact:
Al Medwar
SVP, Investor Relations & Company Communications
9 Meters Biopharma, Inc.
[email protected]
Media Contact:
Veronica Eames
LifeSci Communications, LLC
[email protected]
203-942-4626
SOURCE: 9 Meters Biopharma, Inc.
View supply model on accesswire.com:
https://www.accesswire.com/714199/9-Meters-Biopharma-to-Take part-at-the-Forty fourth-European-Society-for-Medical-Diet-and-Metabolism-ESPEN-Congress
